Eledon Pharmaceuticals, Inc. ((ELDN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Eledon Pharmaceuticals, Inc. is conducting a Phase 1b clinical study titled A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant. The study aims to assess the safety, pharmacokinetics, and efficacy of AT 1501 in preventing rejection in kidney transplant patients, a significant concern in transplant medicine.
Intervention/Treatment: The study tests AT-1501, an experimental monoclonal antibody targeting CD40L, administered as an intravenous infusion. Its purpose is to prevent kidney transplant rejection, offering a potential new treatment avenue.
Study Design: This is an open-label, single-arm study, meaning all participants receive the same treatment without a placebo group. The primary purpose is treatment-focused, with no masking involved, allowing researchers to directly observe the effects of AT-1501.
Study Timeline: The study began on August 19, 2021, with the latest update submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The ongoing study could influence Eledon Pharmaceuticals’ stock performance positively if results show promise, potentially attracting investor interest. Given the competitive landscape of transplant rejection treatments, successful outcomes could position Eledon favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.